f Stability of Parkinson’s Diseased Animal Models Induced by Neurotoxins; a Serious Drawback to Success of Parkinson’s Disease Therapeutic Studies

References

1. LuJ-M. ZhouH-G. Evaluation on behaviors and neuron morphology of Parkinson’s disease rat model.Zhongguo Linchuang Kangfu200481803182
   [Google Scholar]
2. BlesaJ. PhaniS. Jackson-LewisV. PrzedborskiS. Classic and new animal models of Parkinson’s disease.J. Biomed. Biotechnol.2012201284561810.1155/2012/845618 22536024
   [Google Scholar]
3. MeirelesJ. MassanoJ. Cognitive impairment and dementia in Parkinson’s disease: Clinical features, diagnosis, and management.Front. Neurol.201238810.3389/fneur.2012.00088 22654785
   [Google Scholar]
4. WoltersE.C. van LaarT. BerendseH.W. Parkinsonism and related disorders.3rd edAmsterdamVU University Press2010
   [Google Scholar]
5. PfeifferR.F. Gastrointestinal dysfunction in Parkinson’s disease.Parkinsonism Relat. Disord.2011171101510.1016/j.parkreldis.2010.08.003 20829091
   [Google Scholar]
6. Rodriguez-OrozM.C. JahanshahiM. KrackP. Initial clinical manifestations of Parkinson’s disease: Features and pathophysiological mechanisms.Lancet Neurol.20098121128113910.1016/S1474‑4422(09)70293‑5 19909911
   [Google Scholar]
7. WoltersE.C. FrancotC. BergmansP. Preclinical (premotor) Parkinson’s disease.J. Neurol.2000247Suppl. 2II103II109 10991655
   [Google Scholar]
8. WoltersE.Ch. BraakH. Parkinson’s disease: Premotor clinico-pathological correlations.J. Neural Transm. Suppl.20067070309319 17017546
   [Google Scholar]
9. ZlotnikY. BalashY. KorczynA.D. GiladiN. GurevichT. Disorders of the oral cavity in Parkinson’s disease and parkinsonian syndromes.Parkinsons Dis.2015201537948210.1155/2015/379482 25685594
   [Google Scholar]
10. OkyereS.K. ZengC. YueD. HuY. Neurotoxic mechanism and shortcomings of MPTP, 6-OHDA, rotenone and paraquat-induced Parkinson’s disease animal models.Venoms Toxins202112710.2174/2666121701999201104163407
    [Google Scholar]
11. De MirandaB.R. GreenamyreJ.T. RochaE.M. CastroS. GreenamyreJ.T. Response to rotenone and Parkinson’s Disease; reduced sensitivity in females.Toxicol. Sci.2019170256310.1093/toxsci/kfz127 31161199
    [Google Scholar]
12. De MirandaB.R. FazzariM. RochaE.M. CastroS. GreenamyreJ.T. Sex differences in rotenone sensitivity reflect the male-to-female ratio in human Parkinson’s Disease incidence.Toxicol. Sci.2019170113314310.1093/toxsci/kfz082 30907971
    [Google Scholar]
13. AzmyM.S. MenzeE.T. El-NagaR.N. TadrosM.G. Neuroprotective effects of Filgrastim in rotenone-induced Parkinson’s Disease in rats: Insights into its anti-Inflammatory, neurotrophic, and antiapoptotic effects.Mol. Neurobiol.20185586572658810.1007/s12035‑017‑0855‑1 29327204
    [Google Scholar]
14. HeX. YangS. ZhangR. Smilagenin protects dopaminergic neurons in chronic MPTP/Probenecid-Lesioned Parkinson’s Disease models.Front. Cell. Neurosci.2019131810.3389/fncel.2019.00018 30804756
    [Google Scholar]
15. HuM. LiF. WangW. Vitexin protects dopaminergic neurons in MPTP-induced Parkinson’s disease through PI3K/Akt signaling pathway.Drug Des. Devel. Ther.20181256557310.2147/DDDT.S156920 29588573
    [Google Scholar]
16. WeiR. RongC. XieQ. Neuroprotective effect of optimized Yinxieling formula in 6- OHDA-Induced chronic model of Parkinson’s Disease through the inflammation pathway.Evid. Based Complement. Alternat. Med.20192019252964110.1155/2019/2529641 31929812
    [Google Scholar]
17. VoroninM.V. KadnikovI.A. VoronkovD.N. SeredeninS.B. Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease.Sci. Rep.2019911702010.1038/s41598‑019‑53413‑w 31745133
    [Google Scholar]
18. VieiraJ.C.F. BassaniT.B. SantiagoR.M. de O Guaita, G.; Zanoveli, J.M.; da Cunha, C.; Vital, M.A.B.F. Anxiety-like behavior induced by 6-OHDA animal model of Parkinson’s disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety.Behav. Brain Res.20193711119810.1016/j.bbr.2019.111981
    [Google Scholar]
19. KurnikM. GilK. GajdaM. ThorP. BugajskiA. Neuropathic alterations of the myenteric plexus neurons following subacute intraperitoneal administration of salsolinol.Folia Histochem. Cytobiol.2015531496110.5603/FHC.a2015.0010 25815627
    [Google Scholar]
20. Thiruchelvam M. Paraquat and Parkinson's disease, always follow the label instructions when using paraquat: Paraquat Information Center. Available from: https://paraquat.com/en/safety/safety-humans/paraquatand-parkinsons-disease (Accessed March 17, 2020).
21. DawsonT.M. KoH.S. DawsonV.L. Genetic animal models of Parkinson’s disease.Neuron201066564666110.1016/j.neuron.2010.04.034 20547124
    [Google Scholar]
22. ChaudhuriK.R. YatesL. Martinez-MartinP. The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential.Curr. Neurol. Neurosci. Rep.20055427528310.1007/s11910‑005‑0072‑6 15987611
    [Google Scholar]
23. GallagherD.A. LeesA.J. SchragA. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them?Mov. Disord.201025152493250010.1002/mds.23394 20922807
    [Google Scholar]
24. Kurnik-Łucka M, Bugajski A, Gil K. Modifications of neurotoxin-based animal models of the non-motor complications in Parkinson’s disease in terms of drug development.Pharmacol. Drug Dev. Ther.201611610.15761/PDDT.1000105
    [Google Scholar]
25. GuoX.X. WangY. WangK. JiB.P. ZhouF. Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection.J. Zhejiang Univ. Sci. B201819755956910.1631/jzus.B1700254 29971994
    [Google Scholar]
26. HyojuS.K. AdriaansensC. WienholtsK. Low-fat/high-fibre diet prehabilitation improves anastomotic healing via the microbiome: An experimental model.Br. J. Surg.2020107674375510.1002/bjs.11388 31879948
    [Google Scholar]
27. StaudacherH.M. LomerM.C.E. FarquharsonF.M. A diet low in FODMAPs reduces symptoms in patients with Irritable Bowel Syndrome and a probiotic restores Bifidobacterium species: A randomized controlled trial.Gastroenterology2017153493694710.1053/j.gastro.2017.06.010 28625832
    [Google Scholar]